Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ioana Hinshaw (NPI 1033193180)

Field	Value
Entity Type	Individual
Organization	Ioana Hinshaw
Address	1800 N Williams St Ste 200
City	Denver
State	CO
ZIP	80218
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 2, 2005

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This profile is consistent with a therapeutics-focused oncology practice: the highest-revenue Medicare codes are A9607, J9271, and J1930, which correspond to lutetium-based radiopharmaceutical therapy, pembrolizumab immunotherapy, and lanreotide respectively, and there is meaningful PET/CT diagnostic activity on file. The presence of high-revenue radiopharmaceutical therapy (A9607) alongside PET imaging codes suggests the provider delivers integrated diagnostic and therapeutic oncology services rather than solely office-based care.

Revenue is highly concentrated in a small set of Medicare codes: the top 3 Medicare codes by revenue account for 70.4% of this provider's total Medicare revenue, with A9607 at $964.2K (36.9%), J9271 at $597.7K (22.9%), and J1930 at $279.8K (10.7%) out of a total Medicare revenue of $2.7M. That concentration indicates the practice’s financial performance is heavily dependent on a few high-cost therapies.

This provider is effectively single-payer from the available data: Medicare revenue is $2.7M and there is no Medicaid billing on file, so the practice has no recorded Medicaid exposure. That payer mix implies Medicare policy and reimbursement changes would disproportionately affect the provider’s revenue stream.

On competitive standing for the top drugs, the provider is a modest national participant rather than a dominant center: A9607 ranks #34 of 44 providers nationally (23th percentile; typical, unremarkable volume for this code), J9271 ranks #766 of 1841 (58th percentile; typical, unremarkable volume for this code), and J1930 ranks #21 of 56 (62th percentile; typical, unremarkable volume for this code). These rankings indicate peer-level utilization for these specialty drugs rather than clear national leadership.

Ambulatory oncology visit volume is unusually high relative to national peers: code 99214 shows 940 claims, $94 avg paid/claim, $88.4K revenue (3.4% of total Medicare revenue) and ranks #13337 of 479517 providers nationally (97th percentile; notably above typical national volume). This suggests substantial ongoing outpatient management and follow-up care for established patients in addition to infusion- or procedure-based revenue.

Diagnostic and theranostic imaging is a meaningful secondary revenue stream: 78815 contributed $239.9K (9.2% of Medicare revenue) and A9595 added $100.3K (3.8%), with other PET-related codes like 78816 and A9587 also present. The combination of therapeutic radiopharmaceutical billing with multiple PET/CT codes implies either onsite imaging capability or close referral relationships supporting radiopharmaceutical treatment pathways.

Supportive and adjunctive oncology therapies are represented but are a smaller share of revenue: J0897 (denosumab) generated $65.9K (2.5%), Q5122 (pegfilgrastim-apgf biosimilar) $38.2K (1.5%), and J2506 (pegfilgrastim, excludes biosimilar) $31.4K (1.2%). These codes indicate routine use of bone-health and growth-factor support consistent with active systemic oncology treatment programs.

The provider has a long active tenure on file, with NPI enumerated 2005-12-02 (~21 years ago), which supports the interpretation of an established hematology/oncology practice. Combined with the therapy- and imaging-heavy code mix, the tenure suggests sustained provision of specialty oncology services over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

61 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	4,970	$190	$964.2K
J9271	Injection, pembrolizumab, 1 mg	13,900	$40	$597.7K
J1930	Injection, lanreotide, 1 mg	6,360	$40	$279.8K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	200	$1,220	$239.9K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	220	$460	$100.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	940	$90	$88.4K
J0897	Injection, denosumab, 1 mg	3,660	$20	$65.9K
A9587	Gallium ga-68, dotatate, diagnostic, 0.1 millicurie	500	$90	$44.7K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	420	$90	$38.2K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	30	$1,230	$34.3K

Showing 1–10 of 61

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Ioana Hinshaw — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

61 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	2	10	5,170	$190	$1M
J9271	9	40	10,700	$40	$520.5K
J1930	2	10	5,420	$40	$253.1K
A9595	12	20	220	$540	$141.1K
J0897	56	140	2,580	$20	$68.8K
78815	18	120	60	$540	$58.9K
A9587	2	10	290	$120	$48.9K
J2506	3	10	370	$90	$32.3K
Q5122	2	10	320	$90	$30.7K
J3490	35	60	50	$290	$23.1K

Showing 1–10 of 61

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ioana Hinshaw, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Ioana Hinshaw, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hca Healthone LLC	CO	General Acute Care Hospital	$0	$13.3M
Saint Joseph Hospital, Inc	CO	General Acute Care Hospital	$0	$12M
P2p Recovery Resources	CO	Substance Use Disorder Rehabilitation Clinic/Center	$0	$8.6M
Obstetrix Medical Group Of Colorado P C	CO	Neonatal-Perinatal Medicine Physician	$0	$7.8M
Eric S Yaeger Md PC	CO	Hospitalist Physician	$0	$3.7M
Sj East Campus Asc, LLC	CO	Ambulatory Surgical Clinic/Center	$1.1M	$0
Michele Basche	CO	Hematology & Oncology Physician	$854K	$0
Allen Cohn	CO	Hematology & Oncology Physician	$610.9K	$0
Richard Nash	CO	Hematology & Oncology Physician	$504.1K	$0
Michelle Levy	CO	Hematology & Oncology Physician	$497.8K	$0

Ioana Hinshaw — Billing Profile & Reimbursement Data

Sign up for Ioana Hinshaw — Billing Profile & Reimbursement Data policy alerts

Ioana Hinshaw — Billing Profile & Reimbursement Data

Sign up for Ioana Hinshaw — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References